FDA, NIH working to speed new antibiotics

Share this article:

Working with the private-public Biomarkers Consortium at the Foundation for the National Institutes of Health, FDA is looking at options to ease the development path for antibiotics.

Interviewed on BiocenturyTV in September, FDA drugs center director Janet Woodcock said the agency recognizes “the tension between getting the data and this huge need for new antibiotics.”

She said the collaboration “started with skin and skin structures and we've got the entire community together.”

But drug development is getting harder, Woodcock noted. “Many things have changed,” she said. “The reimbursement environment has changed, the cost of doing clinical trials has gone up remarkably.”

Asked what role FDA should play in comparative effectiveness research, Woodcock noted that comparative data will be required for certain therapies being developed for cancer or other life-threatening diseases.

Giving a Wall Street perspective, Warburg Pincus managing director for healthcare Jonathan Leff said that FDA has “a big enough challenge to balance the risk vs the benefit of new therapies... If you add a cost dimension to that or even a dimension of comparing it to other therapies, you would complicate that equation.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.